title: Committee Opinion No. 663: Aromatase Inhibitors in Gynecologic Practice.
abstract: Aromatase inhibitors have been used for the treatment of breast cancer, ovulation induction, endometriosis, and other estrogen-modulated conditions. For women with breast cancer, bone mineral density screening is recommended with long-term aromatase inhibitor use because of risk of osteoporosis due to estrogen deficiency. Based on long-term adverse effects and complication safety data, when compared with tamoxifen, aromatase inhibitors are associated with a reduced incidence of thrombosis, endometrial cancer, and vaginal bleeding. For women with polycystic ovary syndrome and a body mass index greater than 30, letrozole should be considered as first-line therapy for ovulation induction because of the increased live birth rate compared with clomiphene citrate. Lifestyle changes that result in weight loss should be strongly encouraged. Aromatase inhibitors are a promising therapeutic option that may be helpful for the management of endometriosis-associated pain in combination therapy with progestins.
mesh_terms: D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D004715:Endometriosis / Q000188:drug therapy; D004967:Estrogens / Q000172:deficiency; D005260:Female; D006176:Gynecology / Q000592:standards; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy; D010024:Osteoporosis / Q000139:chemically induced
chemical_list: D047072:Aromatase Inhibitors; D004967:Estrogens